http://orcid.org/0000-0002-8481-5850
Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Stephen Maxwell Montgomery, Luke Green, Hajer Karoui, Richard Nicholas & Jaclyn Loh. (2023) To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis. Journal of Medical Economics 26:1, pages 139-148.
Read now
Read now
G. Dalla Costa, L. Leocani & G. Comi. (2022) Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis. Expert Review of Clinical Immunology 18:2, pages 105-114.
Read now
Read now
Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now
Read now
Evelyn Walter, Thomas Berger, Barbara Bajer-Kornek & Florian Deisenhammer. (2019) Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria. Journal of Medical Economics 22:3, pages 226-237.
Read now
Read now
Kathleen Mary Noon, Stephen Maxwell Montgomery, Nicholas Edward Adlard & Michel Anton Kroes. (2018) When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing–remitting multiple sclerosis. Journal of Medical Economics 21:10, pages 983-992.
Read now
Read now
Articles from other publishers (6)
Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
Crossref
Yahiya Y. Syed. (2020) Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis. Drugs 81:1, pages 157-168.
Crossref
Crossref
Laura Foucault-Fruchard, Hervé Watier & Daniel Antier. (2020) Dénominations et indications des anticorps face à la réglementation et aux pratiques des laboratoires pharmaceutiques. médecine/sciences 35:12, pages 1189-1193.
Crossref
Crossref
Lisa Batcheller & David Baker. (2019) Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?. Journal of the Neurological Sciences 404, pages 19-28.
Crossref
Crossref
Sanja Stanisic, Antonio Bertolotto, Patrizia Berto, Paolo Di Procolo & Julia Morawski. (2019) The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031983852.
Crossref
Crossref
Luis Hernandez, Malinda O’Donnell & Maarten Postma. (2018) Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. PharmacoEconomics 36:10, pages 1223-1252.
Crossref
Crossref